Official PDF Translation•Stem Cell Research & Therapy

Pre-clinical evaluation of the efficacy and safety of human induced pluripotent stem cell-derived cardiomyocyte patch

Authors: Shigeru Miyagawa; Takuji Kawamura; Emiko Ito; Maki Takeda; Hiroko Iseoka; Junya Yokoyama; Akima Harada; Noriko Mochizuki-Oda; Yukiko Imanishi-Ochi; Junjun Li; Masao Sasai; Fumiyo Kitaoka; Masaki Nomura; Naoki Amano; Tomoko Takahashi; Hiromi Dohi; Eiichi Morii; Yoshiki Sawa

DOI: 10.1186/s13287-024-03690-8Status: Verified Translated Edition

Sponsored AdvertisementAd Placement Area

reCAPTCHA Bot Shield Active

Preparing Secure Academic Download

Verifying human reader & generating high-resolution document...

Verifying Document Integrity15s remaining

← Back to Article

Protected by Google reCAPTCHA v3.•Privacy•Terms

Sponsored ContentAdSense In-Feed Ad Slot

Key Findings in This Report

• Clinical-grade hiPSC-CM patches demonstrated safety with no tumorigenicity or genomic mutations in preclinical assessments. • hiPSC-CM patches improved cardiac function and promoted angiogenesis in a porcine myocardial infarction model. • No lethal arrhythmias were observed post-transplantation, supporting the safety profile of the patches. • The study provides proof-of-concept for the translational potential of hiPSC-CM patches in treating heart failure.